Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-02-28

Clinical Trial Update: A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of MLN9708 in Japanese participants with relapsed/refractory multiple myeloma was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MLN9708 (ixazomib)

Snippet

Sponsor: Takeda | Conditions: Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Status: TERMINATED | Results posted: 2020-02-28